CHD1L is overexpressed in a wide range of malignancies, and this overexpression is strongly associated with tumor progression, metastatic disease, and poor clinical outcomes for breast, ovarian, bladder, lung, colorectal, and many other cancer indications [2, 4, 6, 8, 18, 62–67]. Here, CHD1L is linked to cancer.